Plain-English translation of NCT06659705 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new imaging scan called 68Ga-FAPI-46 PET to see if it can detect pancreatic cancer earlier and catch cancer recurrence (when cancer comes back) before standard scans can. The new scan works alongside your regular CT scans to give doctors a clearer picture of your disease and help them monitor you more closely after surgery.
Pancreatic cancer is often found late, which limits treatment options. This trial exists to see whether the new imaging method can find cancer at earlier stages or detect it sooner when it returns after treatment, potentially improving outcomes for patients.
You likely qualify if…
You likely don't qualify if…
You will have imaging scans at several time points: baseline scans within one month of enrollment, and then additional scans every three months after surgery for as long as needed. Some patients receiving pre-surgery treatment will have extra scans before surgery. Each scan visit takes a few hours, and you'll receive a small amount of radioactive tracer (a safe, standard imaging agent) that helps the scanner see cancer activity. Your doctor will continue your normal cancer care without any changes based on this new scan.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
France